Simple and accessible microfluidic platform for single molecule sequence profiling of tumor-derived DNA within liquid biopsies

Ended Project Grant Awarded Last action

Award ID
R43CA281570
Recipient
Awarding agency
Obligated
$275,721

Award facts

Assistance listing
93.394 Cancer Detection and Diagnosis Research
Completion date
Originally
Place of performance
Maryland, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Over 600,000 people in the US will DIE from cancer this year. IT is estimated that 25% of these deaths could have been prevented by detection in earlier stages. Implementation of minimally-invasive routine screening, such as PAP smears for cervical cancer, has proven to be an effective approach for reducing cancer mortality. However, several challenges prevent successful implementation of screening in most cancers, especially ones which are not readily accessible for imaging or tissue biopsy. One promising avenue for cancer diagnostics is through use of circulating DNA from so-called "liquid biopsies" or other accessible sample media circulating throughout the body collecting genetic material from tissues, including tumors. Tumor-specific molecular biomarkers, such as DNA mutations and methylation, can be found in minimally-invasive sample media, such as blood, stool, and urine, but are typically only present in very low copy numbers (

Transactions

Action Obligated Date
Amendment $0
Original award $275,721

Quick answers

Who received award R43CA281570?

R43CA281570 was awarded to Hypermelt, LLC by National Cancer Institute (National Institutes of Health) on July 1, 2023.

How much is award R43CA281570 worth?

$275,721 has been obligated on R43CA281570.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login